• 主题
高级搜索  >
历史搜索 清空历史
首页> 外国专利> Bio-Marker Composition for Prediction of Drug for breast/ovary cancer Sensitivity Estimation Method for Prediction of Drug for breast/ovary cancer Sensitivity using Bio-Marker Composition and Diagnosing Chip for Detection of Bio-Marker Composition for Prediction of Drug for breast/ovary cancer Sensitivity

Bio-Marker Composition for Prediction of Drug for breast/ovary cancer Sensitivity Estimation Method for Prediction of Drug for breast/ovary cancer Sensitivity using Bio-Marker Composition and Diagnosing Chip for Detection of Bio-Marker Composition for Prediction of Drug for breast/ovary cancer Sensitivity

机译：用于预测乳腺癌/卵巢癌药物的生物标志物组合物的灵敏度估算方法使用生物标志物组合物和用于检测用于预测乳腺癌/卵巢癌药物的生物标志物组合物的诊断芯片来预测用于乳腺癌/卵巢癌的药物的敏感性灵敏度

页面导航
  • 摘要
  • 著录项
  • 相似文献

摘要

The present invention relates to a biomarker composition for determining female cancer drug reactivity, wherein the biomarker composition is composed of a combination of markers including variation for adjusting gene expression, so as to determine reactivity with respect to a female cancer drug. The biomarker composition includes 1_13248174_T_C (marker 1), 16_85071785_A_G (marker 2), and 9_34371054_A_C (marker 3) and is to determine female cancer drug reactivity. According to the present invention, sensitivity for each genetic trait of a subject can be predicted with respect to a female cancer drug through biomarkers for female cancer-related drugs, and thus preliminary verification effective for discovery of a new drug candidate group as well as the field of personalized medicine can be performed.
机译：本发明涉及用于确定女性癌症药物反应性的生物标志物组合物，其中该生物标志物组合物由包括用于调节基因表达的变化的标记物的组合组成，从而确定相对于女性癌症药物的反应性。该生物标志物组合物包括1_13248174_T_C（标志物1），16_85071785_A_G（标志物2）和9_34371054_A_C（标志物3），并且用于确定女性癌症药物反应性。根据本发明，可以通过女性癌相关药物的生物标记物，针对女性癌药物预测对象的每种遗传性状的敏感性，并且因此初步验证对于发现新的候选药物组和药物有效。可以执行个性化医学领域。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号